We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter...
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc. PR Newswire NEW YORK, Aug. 9, 2021 NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating...
By Colin Kellaher Shares of Intersect ENT Inc. rose more than 12% on Friday after the drug-delivery company agreed to be acquired by medical-technology giant Medtronic PLC. Dublin-based Medtronic...
By Colin Kellaher Medtronic PLC on Friday said it agreed to buy Intersect ENT Inc. in an all-cash deal with an implied enterprise value of about $1.1 billion. Dublin-based medical-technology...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter...
Medtronic to Acquire Intersect ENT Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio Canada NewsWire DUBLIN and MENLO PARK, Calif., Aug. 6...
VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions